U.S. Market Advisors Law Group PLLC Alerts Investors of Approaching Lead Plaintiff Deadline in Lawsuit Against Roche Holding AG


WASHINGTON, DC (June 20, 2017) — U.S. Market Advisors Law Group PLLC (USMA Law Group) announced today that a securities fraud class action has been filed against Roche Holding AG (Other OTC: RHHBY). Investors suffering losses from purchases of Roche securities between March 2, 2017 and June 5, 2017, who wish to choose the attorneys to represent you and the class, must apply to be appointed lead plaintiff no later than August 7, 2017.

Any member of the proposed class may move the Court to serve as lead plaintiff through attorneys of its choice, or may choose to do nothing and remain an absent class member. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Roche securities during the relevant period. Members of the class will be represented by the lead plaintiff and attorneys chosen by the lead plaintiff.

If you would like to discuss your legal rights, click here: http://usmarketlaw.com/roche-securities-class-action/. You may also contact directly attorney David Abel at +1 (202) 274-0237 or info@usmarketlaw.com. There is no cost or obligation to you.

The lawsuit, Biondolillo v. Roche Holding AG et al., No. 3:17-cv-04056 was filed on June 6, 2017, in the U.S. District Court for the District of New Jersey. The complaint alleges Roche violated federal securities laws by making fraudulent statements about the breast cancer drug therapy it is developing. Specifically, defendants allegedly made false and/or misleading statements and/or failed to disclose that: (1) the combination of drugs Perjeta and Herceptin is only marginally more effective than Herceptin alone in preventing breast cancer; and (2) as a result, defendants’ statements about the company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On June 5, 2017, media reports publicly revealed that combining Roche’s breast cancer drug Perjeta with its older treatment Herceptin only had a negligible benefit while the joint therapy significantly increased treatment costs and had higher rates of certain side effects than Herceptin alone. Roche’s share price dropped following this news.

USMA Law Group is based in Washington, D.C. and represents investors worldwide in U.S. antitrust, securities, and shareholder litigation. To learn more about USMA Law Group, visit usmarketlaw.com.

U.S. Market Advisors Law Group PLLC
David P. Abel, Esq.
+1 (202) 274-0237

This press release may constitute Attorney Advertising in certain jurisdictions.